New vaccine aims to stop deadly salmonella strains
NCT ID NCT05480800
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new vaccine designed to protect against two types of Salmonella bacteria that cause serious infections like typhoid fever and invasive nontyphoidal Salmonella disease. The trial involved 155 healthy adults in Europe and Africa who received three doses of the vaccine or a placebo. Researchers checked for side effects and measured the immune response to see if the vaccine is safe and prompts the body to fight the bacteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) and invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA)
- What this could lead to
- If successful, this vaccine could help prevent serious Salmonella infections that cause fever and bloodstream infections, especially in Africa where they are a major health problem.
- What could go wrong
- This is an early phase 1/2a trial with only 155 participants, so results may not apply to larger populations. The vaccine may not provide strong enough protection or could have side effects not yet seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALMONELLA INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Blantyre, Malawi
More trials for these conditions
Other studies related to the condition(s) this trial covers.